Pharmaceutical

Vivoryon issues updates on its Alzheimer’s therapy programme

The complete data readouts of two-Phase II trials are expected in 2024, with an additional open-label extension study currently in the works.

Jul 17, 2023 - 20:00
Vivoryon issues updates on its Alzheimer’s therapy programme
The complete data readouts of two-Phase II trials are expected in 2024, with an additional open-label extension study currently in the works.
Read the original article

Tags:

Previous Article

Antengene’s multiple myeloma therapy receives approval in Hong Kong

Next Article

Korro Bio enters merger deal with Frequency Therapeutics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BMS bags UK advanced melanoma win for Opdualag

BMS bags UK advanced melanoma win for Opdualag

Dec 28, 2023

STAT+: AbbVie buys Immunogen, maker of targeted cancer drugs, for $10 billion

STAT+: AbbVie buys Immunogen, maker of targeted cancer ...

Dec 1, 2023

STAT+: Flagship, Pfizer team up in deal worth up to $7 billion

STAT+: Flagship, Pfizer team up in deal worth up to $7 ...

Jul 18, 2023